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Introduction
Since the first successful isolated lung transplant performed 
by Dr. Joel Cooper at the University of Toronto in 1983, 
lung transplantation has been considered an optimal therapy 
for multiple causes of end stage pulmonary disease (1). 
The initial isolated transplant operations were single lung 
transplants performed on patients with severe idiopathic 
pulmonary fibrosis (IPF). Since then, lung transplantation 
has been more heavily utilized to treat patients with 
multiple conditions including interstitial lung disease 
(ILD), chronic obstructive pulmonary disease (COPD), 
cystic fibrosis (CF), pulmonary hypertension, and more (2). 
Over the past several decades, changes in donor selection, 
postoperative care, and immunosuppression therapy 
have broadened the use of lung transplant and improved 
outcomes for transplant recipients (3). While new guidelines 
have been created to help guide transplant candidate 
selection and management, there is still substantial debate 
surrounding the utilization of single versus bilateral lung 
transplantation in patients eligible for either strategy (2,4,5). 
To date, much of the decision-making regarding use of 
single versus bilateral lung transplant is based on individual 
institutional case series experience or retrospective reviews 
of large lung transplant registries. There is a lack of high 
quality, prospective data to provide clear criteria favoring 
single or bilateral lung transplantation when either strategy 
is possible. Furthermore, there is a lack of consensus on the 
philosophical dilemma: should a bilateral operation with 
better palliation be offered to fewer patients, or should a 
lesser unilateral operation be offered to more recipients? 
The purpose of this chapter is to review the existing 
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literature regarding single and bilateral lung transplantation. 
Specifically, this review will highlight the following subjects:
	Disease-specific indications for single (SLT) vs. 
bilateral lung transplantation (BLT), with a focus on 
emphysema and pulmonary fibrosis; 
	Impact of procedure type on post-transplantation 
functional status; 
	Impact of procedure type on post-transplantation 
quality of life (QOL); 
	Chronic rejection after lung transplantation; 
	Ethical challenges facing the choice between single 
and bilateral transplants; 
	The novel strategy of “staged BLT (SBLT)”.
Disease-specific indications for lung 
transplantation
There  i s  a  wide  var ie ty  o f  ind ica t ions  for  lung 
transplantation, including end-stage COPD, ILD, 
pulmonary hypertension, CF and bronchiectasis and 
others (2). Because patients with septic lung disease 
(including CF and bronchiectasis) almost always undergo 
BLT due to the infectious risk posed by the retained 
native lung, they will not be discussed further in this 
chapter (6). The International Society for Heart and Lung 
Transplantation (ISHLT) provides the most comprehensive 
data on long-term survival associated with BLT and SLT for 
all recipients (7). They collect data from 256 lung transplant 
and 180 heart-lung transplant centers, and represent an 
estimated 75% of international thoracic transplant activity. 
The registry is ideal for examining longitudinal trends, 
as the registry requires submission of follow-up data on 
a yearly basis. In the 2017 ISHLT report summarizing 
survival trends from 1990–2015, recipients of a lung 
transplantation operation had a median survival of 6.0 years. 
In unadjusted analysis, BLT recipients had better survival 
post-transplant compared to SLT recipients. This difference 
was first seen at 1 year post-op, but increased over a 14-year 
follow-up period. Survival for BLT and SLT groups were 
90% and 88% at 3 months, 82% and 78% at 1 year, 69% 
and 61% at 3 years, 59% and 48% at 5 years, and 41% and 
23% at 10 years, respectively. That high level comparison 
simply begins the discussion, but there are multiple issues of 
selection bias and confounding that cloud the comparison 
of single or bilateral transplantation outcomes. Additional 
literature has focused on short and long-term outcomes 
associated with transplantation type within subgroups 
of patients with specific diagnoses. Much of the existing 
literature examines the use of SLT and BLT in patients with 
either advanced COPD or IPF.
COPD
Emphysema (which encompasses COPD and alpha-1 
antitrypsin deficiency) has been the most common 
indication for lung transplantation (2). The first successful 
experience with transplantation in the COPD population 
involved isolated SLT, initially described by Dr. Joel Cooper 
and his team (1). However, with the development of BLT 
and improvements in technique, BLT has received increased 
clinical adoption and use in patients with COPD (6,8). The 
prevailing physiologic reasoning supporting use of BLT 
is that the technique reduces the risk of early ventilation/
perfusion mismatch and eliminates the issue of subsequent 
hyperinflation in the unresected emphysematous native 
lung that occurs after SLT (8). During the accumulation 
of the early experience, there was a tendency to offer BLT 
to younger patients with the notion that they might have 
greater physiologic reserve to be able to withstand the 
increased stress of a more prolonged surgery (1,4,6). That 
selection bias might have also burdened the SLT cohort 
with an older and frailer group of patients who would 
be at greater risk for premature death regardless of the 
differential contribution of SLT versus BLT. 
Meyer and colleagues in 2001 performed one of the 
early index studies comparing BLT and SLT in the COPD 
population (4). Using the ISHLT/United Network 
for Organ Sharing (UNOS) registry, they performed a 
retrospective analysis of patients with COPD undergoing 
lung transplantation. They attempted to study the 
correlation between transplantation technique (SLT 
vs. BLT) and survival, stratified by age (41–50, 51–60, 
61–70 years). They identified 2,260 lung transplant 
recipients (1,835 SLT, 425 SBLT) from 1991–1997 and 
performed risk-adjusted survival analysis using Cox 
regression, Kaplan-Meier analysis, and calculation of 
risk ratios for mortality. Among all transplant recipients, 
recipient age and procedure type (SLT vs. BLT) were found 
to be associated with increased risk for mortality, with 
advanced age, SLT, and their interaction demonstrating 
significant associations. On Kaplan-Meier analysis, the 
authors demonstrated that BLT was associated with higher 
survival in both the 41–50 and 51–60 years age categories 
across all time points, with a more pronounced survival 
benefit occurring further out from surgery. Survival rates 
among younger patients (<50 years) who underwent SLT 
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were 93.6%, 80.2% and 43.6% at 30 days, 1 year, and 
5 years, respectively, compared to 94.9%, 84.7%, and 
68.2% in the young BLT group (P=0.001). Among those 
aged 51–60 years, the differences in long-term survival were 
slightly less pronounced. Those who received SLT had 
30-day, 1 year, and 5-year survival rates of 93.5%, 79.4%, 
and 39.8%, respectively, compared to 93.0%, 79.7%, 
and 60.5% for patients of similar age who received BLT 
(P=0.05). After age 60, however, the trend reversed. Survival 
associated with SLT was considerably higher (93.0%, 
72.9%, and 36.4%) compared to BLT (77.8%, 66.0%, with 
5-year mortality data unavailable) (P=0.2). When using 
risk ratios to calculate risk of mortality across all ages, 
the authors noted an increased probability of mortality 
for recipients of SLT between ages 40–57 (P=0.001 at 
each age). At approximately age 57, the trend reversed. 
Additionally, the authors focused on US transplant cases to 
examine 3-year morbidity associated with transplantation 
technique. They measured events of hospitalization for 
rejection, onset of bronchiolitis obliterans (BOS), bronchial 
airway complications, and hospitalization for infections. 
No significant differences were observed between BLT and 
SLT in any of these measures. However, the study did not 
measure variables associated with short-term morbidity, 
which may be more relevant in older patients. The study 
concluded that BLT was associated with greater short and 
long-term survival in patients less than 60 years of age.
Thabut and colleagues confirmed the positive long-term 
survival advantage that BLT offered to the younger COPD 
population (9). They completed a large retrospective 
analysis of the ISHLT registry between 1987 and 2006. 
Thabut performed a survival analysis of 9,883 patients 
with a diagnosis of COPD. Additionally, they documented 
important trends in the use of BLT for COPD. For 
example, the proportion of patients with COPD who 
underwent BLT more than doubled from the 1990s to 
more recently (21.6% in 1993 to 56.2% in 2006). Using 
modern propensity score matching (a technique lacking 
in previous papers on the subject) to control for possible 
treatment selection bias associated with each transplant 
method, Thabut determined that median survival time 
was significantly greater for those who received BLT 
(6 .41  year s ,  6 .02–6 .88  year s )  compared  to  SLT 
(4.59 years, 4.41–4.76 years) (P<0.0001). However, the 
survival advantage associated with BLT did not hold 
for patients greater than 60 years of age. The practical 
suggestion was similar: to offer BLT to younger COPD 
patients but to accept the lack of a difference in older 
recipients and perhaps use other criteria to choose the 
transplantation strategy in this population.
The authors’ institution (Washington University in 
St. Louis/Barnes Jewish Hospital) is a high-volume lung 
transplantation center, and BLT has been the preferred 
transplantation method. Cassivi performed a 13-year review 
of lung transplantation for COPD patients at Barnes-
Jewish Hospital between 1988 and 2000 looking at in-
hospital mortality and 5-year survival rates among patients 
with COPD and alpha-1-antitrypsin deficiency (10). 
More than 70% of emphysema patients received BLT, 
reflecting the strong institutional preference for the 
method. Cassivi acknowledged that the preference for 
BLT was due to a record of increased survival and ease of 
postoperative ventilator management. When examining 
long-term survival, COPD patients who received BLT had 
significantly higher 5-year survival at 66.7% compared to 
44.9% for single lung replacement (P<0.001). Conversely, 
many other studies did not find the same survival benefit 
conferred by BLT. 
Bennett and colleagues performed a retrospective 
single center review of COPD patients undergoing lung 
transplantation, with a special focus on patients older 
than 55 years of age (11). These authors noted that it was 
standard policy since the inception of their transplantation 
program to only perform SLT on emphysema patients 
older than 55 years of age. They attempted to identify 
specific patient subgroups that benefit from SLT. They 
examined 5-year survival rates between patients receiving 
SLT (206 patients) and BLT (30 patients) from 1992–2012. 
As expected, the SLT cohort tended to be older and had 
reduced pre-transplant pulmonary function and physical 
conditioning compared to the BLT cohort. Within this 
institution, 30-day, 1-year, and 5-year survival estimates 
between treatment cohorts were similar, with long-term 
survival trending slightly higher for BLT patients. Due to 
their small pool of BLT patients, they also compared their 
institutional data to the outcomes of SLT and BLT patients 
in the UNOS registry. When comparing institutional data 
to SLT and BLT patients in the UNOS registry, Bennett 
noted that their own institution’s SLT patients had generally 
similar preoperative risk in terms of advanced age, comorbid 
condition, and pulmonary function. Their institution’s 
SLT short and long-term survival rates were similar to 
those of the UNOS registry’s BLT subset. This may reflect 
improved experience and perioperative care, given that 
SLT is their institutional preference. They concluded that 
while BLT may provide an individual survival benefit, SLT 
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had substantial utility and should be promoted as much 
as possible given the overall impact that it can have in 
increasing the number of patients receiving transplantation.
Several studies of BLT vs. SLT were performed on 
institutional or national databases that captured data 
before the 2005 implementation of the lung allocation 
score (LAS). Schaffer compared SLT and BLT in the post-
LAS era (12). Using the UNOS registry from 2005-2012, 
Schaffer compared graft survival between transplantation 
types. Graft survival represented a composite of post-
transplantation mortality and graft failure rates. These 
patients were propensity matched to reduce the impact 
of treatment selection bias on the results of the study. 
Among 3,174 COPD patients, 1,299 underwent SLT and 
1,875 underwent BLT. The median follow-up was carried 
over 2 years post-transplant, and there was no significant 
association found between type of transplant and median 
graft survival (67.7 months for BLT vs. 64.0 months for 
SLT; P=0.23). This distinction from previous study results 
may be explained by the novel way that patients were 
selected for transplantation using the LAS. Compared to 
the pre-LAS era, during which time on the waiting list gave 
priority for transplantation, patients with COPD in the 
LAS era must be comparatively more impaired to achieve 
a higher transplantable score (13). The use of the LAS to 
prioritize recipients for transplantation may have reduced 
the apparent benefit of BLT for patients with COPD. 
ILD and interstitial pulmonary fibrosis (IPF)
ILD, which includes IPF, carries the worst overall prognosis 
among end stage pulmonary disease indications for lung 
transplantation (14). Median survival time for patients with 
IPF ranges from 2–3 years post diagnosis without lung 
transplantation, with 5-year post-transplant survival rates 
ranging from 30–50% (14,15). Non-surgical therapies are 
limited (14,16). Lung transplantation has thus far been the 
only restorative therapy to offer a proven survival benefit. 
The short natural history of IPF without transplantation 
gave that diagnosis a competitive edge when the LAS was 
rolled out in 2005. With the application of the LAS in the 
United States, the rate of lung transplantation in this IPF 
population has risen dramatically. Despite the rising number 
of lung transplants in patients with IPF, there is no definitive 
survival advantage consistently shown to be associated with 
either BLT or SLT. Overall, however, the use of BLT in 
patients with IPF is on the rise. In 2011, approximately 
54% of lung transplant operations among IPF patients were 
bilateral (17). In a retrospective institutional case series 
performed at Cleveland Clinic, Mason and colleagues [2007] 
studied 82 patients who underwent lung transplantation 
for IPF (18). They compared overall 30-day, 1-year, and 
5-year survival between patients with IPF and propensity-
matched, non-IPF patients. Overall survival among IPF 
patients was significantly worse at all time points compared 
to their non-IPF matched counterparts. Additionally, they 
calculated that BLT conferred a survival advantage among 
IPF patients (81% vs. 67% and 55% vs. 34% at 1 and 
5 years, respectively). However, they could only compare 
BLT versus SLT in 10 matched pairs due to the strong 
selection bias attributed to their institutional preference 
to perform BLT in younger patients. Interestingly, they 
failed to note advanced age as an independent risk factor for 
mortality in BLT.
Additional studies have also supported the use of BLT 
in IPF patients because of an apparent survival advantage. 
Weiss focused on transplantation in IPF patients after the 
institution of the LAS score (19). They examined all-cause 
mortality 1-year after transplant in 1,256 IPF patients listed 
in the UNOS registry between 2005 and 2007. Additionally, 
they further examined the effect of pre-transplant disease 
severity on mortality outcomes by stratifying patients into 
LAS quartiles. Quartiles 1–3 indicated lower risk IPF 
patients, while quartile 4 contained the highest risk IPF 
patients. They determined that IPF patients with higher 
LAS were more likely to receive BLT. They observed a 
trend towards greater usage of BLT in sicker patients, 
with 21% more patients receiving BLT in the highest LAS 
quartile compared to the lowest (59.5% vs. 38.4%, P<0.05). 
Within the highest quartile, SLT was associated with a 
14.4% increased risk in cumulative mortality compared to 
BLT. However, in the lowest quartile, SLT was found to 
be an independent protective factor in terms of mortality. 
There was no demonstrated short-term survival benefit 
associated with either transplantation type. Their findings 
are counterintuitive to the notion that BLT should be 
reserved for younger patients with more physiologic 
reserve, and instead suggest a role for BLT specifically for 
those with potentially higher pre-operative risk. 
Force conducted one of the largest retrospective reviews 
of lung transplantation among IPF patients (20). This report 
also demonstrated a survival advantage associated with BLT 
among IPF patients. The authors performed a retrospective 
review of the UNOS registry from 1987 to 2008 studying 
3,860 patients (2,431 SLT and 1,429 BLT) using propensity 
score matching. Propensity-matched analysis failed to show 
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a substantial survival benefit for BLT (HR 0.90, 95% CI, 
0.78–1.0, P=0.11). However, when a one-year conditional 
survival analysis was performed, the authors found that BLT 
had significantly better long-term survival (12.08 versus 
6.8 years, P=0.0006). When analyzing for risk factors for 
death within the BLT group, they reported recipient age, 
donor age, and year of transplantation to be significant 
predictors of mortality. Specifically, they observed that 
patients over the age of 57 had higher 1-year post-transplant 
mortality risk. Based on the conditional survival analysis 
and the significant correlation between advanced age and 
mortality risk, the authors concluded that younger IPF 
patients would most likely benefit from BLT to enhance 
long-term survival. 
Not all available studies found a survival advantage 
associated with BLT. Chauhan performed a review of the 
UNOS registry from 2001–2009, examining actuarial post-
transplant graft survival (21). In a unique approach, they 
studied 1,001 lung transplant recipients with IPF who 
were concurrently listed for BLT and SLT. Four hundred 
thirty-four (43%) of these patients underwent SLT while 
the remaining 57% underwent BLT. The authors noted 
significant differences in baseline comorbidities, functional 
status, pulmonary function tests, and recipient disease 
severity. Despite these baseline differences, there were no 
observed differences in short or long-term graft survival. 
Based on these comparable outcomes, the authors advocated 
for more liberal use of SLT among IPF patients. However, 
they did note that a major limitation of their study was 
the assumption that organ assignment was random and 
based solely on the availability of one or two donor lungs. 
At the institutional level, or even the surgeon level, there 
may be great variability in willingness to accept any 
individual donor lung based on several donor and recipient 
characteristics. For example, a hospital may list a patient 
for either SLT or BLT, suggesting equipoise, but that 
same group may have a low threshold to decline a single 
lung donor. This effectively would make their original 
assumption about the equivalence of the transplanted lungs 
less valid. 
Meyer performed a large-scale retrospective review of 
the early UNOS registry experience in 2001 that included 
a cohort of 821 lung transplant patients (636 SLT, 185 
BLT) with pulmonary fibrosis (4). They produced an age-
stratified comparison of survival by procedure type. On 
crude univariate analysis, they found that younger IPF 
patients (30–49 years) with SLT had better short and long-
term survival post-transplant than similar patients after 
BLT (90.9% vs. 77.1% at 1 month; 63.8% vs. 46.2% at 
3 years; P=0.02). The same trend favoring single lung 
replacement was observed in older patients. However, when 
a 1-month post-transplant conditional survival analysis 
was performed, there were no significant subsequent 
differences seen between procedure types at any age group. 
This suggests that there may be greater periprocedural 
mortality associated with BLT. Propensity score matching 
and multivariate regression analysis failed to show survival 
differences between procedure types. Nwakanma focused 
their analysis on bilateral versus single lung transplants in 
IPF patients older than 60 years of age (22). Performing 
a large-scale analysis of 1,656 IPF patients in the UNOS 
registry between 1998 and 2004, they concluded that SLT 
was favored in this age group, with 78% of the patients 
in that sample undergoing SLT. Propensity score analysis 
demonstrated similar short and median-term survival 
between BLT and SLT. Transplantation type was not 
associated with mortality. Thus, they could not advocate for 
the use of either procedure type in older IPF patients.
When examining diagnosis-specific survival outcomes 
for BLT versus SLT, the existing literature demonstrates 
mixed findings. Comparing bilateral and single lung 
transplant effects by indication is crucial as the underlying 
pathophysiology of each disease is very different, and could 
greatly affect outcomes. The use of bilateral transplant for 
both COPD and IPF is on the rise. Both techniques have 
been utilized in younger and older populations despite 
previous notions that older individuals may “lack the 
reserve” to tolerate the procedure (4,9,10,19,20). Some data 
have demonstrated a greater advantage for using bilateral 
transplant in younger COPD populations, but the evidence 
in that disease is still conflicting (4,9). The picture is even 
more mixed in analyses of IPF patients. The available 
literature is relatively lackluster because most studies are 
small, retrospective, single-center case reviews. These 
studies are often limited in sample size and may be affected 
by institutional comfort and experience with a preferred 
technique. Other studies have relied on large retrospective 
database analysis of the ISHLT and UNOS registries, and 
many are based on data obtained before the institution of 
the LAS prioritization scheme. With the implementation 
of the LAS, the patient characteristics of those undergoing 
transplant are different, with a priority given to those with 
higher severity of illness instead of longer time spent on the 
waitlist (12). A randomized control trial is neither practical 
nor feasible in this setting. High quality, prospectively 
collected data collected from a variety of institutions that 
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comprehensively take into account the effects of age and 
multiple comorbidities will be useful in further unmasking 
the effect of transplantation type for advanced COPD 
and IPF patients. Until that time, the data are diverse and 
conflicting enough to simply state that there is equipoise 
between the two strategies. Factors other than patient 
survival or graft survival must be considered as well.
Post-transplant functional status and procedure 
type
In addition to collecting data on short- and long-term 
survival, several authors have examined the influence 
of BLT versus SLT on post-transplantation functional 
status. Functional status is most commonly quantified by 
spirometry, which has been strongly correlated with QOL 
in lung transplant patients (23). However, other measures 
such as the 6-minute walk test (6MWT) and comprehensive 
surveys on each patient’s ability to perform daily activities 
have also been used. Mason and colleagues performed 
a single institution study of the relative impact of lung 
transplantation on recipient pulmonary function, with a 
particular focus on measuring percent-predicted forced 
1-second expiratory volume (FEV1%) (24). They had 9,471 
postoperative FEV1 and forced vital capacity (FVC) values 
from 509 adult transplant recipients, and performed a 
longitudinal temporal evaluation of FEV1% values for each 
patient. Mason and colleagues found that for both BLT 
and SLT patients, FEV1% typically peaked at 1 year after 
transplant. Forced 1-second expiratory volume increased 
from 50% in the immediate postoperative period to 55% 
at 1 year post-operatively in SLT recipients, and then 
gradually declined to 47% by three years. BLT recipients 
exhibited a similar trend but had higher overall FEV1 values 
at every time point (60% immediately post-transplant, 75% 
1-year post-transplant, and 65% 3 years post-transplant). 
The authors also noted an increased mortality risk 
associated with decline in post-transplant FEV1 values in 
all recipients. Although patients undergoing either SLT or 
BLT exhibited increased risk of death with declining FEV1, 
this association in BLT recipients was notably tempered. 
The authors suggested that BLT may confer a protective 
effect on FEV1—and thus survival—likely as a function 
of providing recipients with enhanced pulmonary reserve. 
They recommended consideration of functional status in 
identifying which age groups would obtain maximal benefit 
from lung transplantation.
Pêgo-Fernandes also demonstrated relative improved 
pulmonary function (as measured by spirometry) among 
patients who underwent BLT (23). They performed a 
small, single-institution review of FVC and FEV1 data 
among lung transplant recipients between 2003 and 2006. 
Twenty-nine patients underwent transplant and were alive 
after the first postoperative year, and were thus included 
in analysis. Of these, 11 patients underwent SLT and 18 
patients underwent BLT. All patients underwent spirometry 
pre-transplantation, and at 1-, 3-, 6-, 9-month, and 1-year 
intervals post-transplantation. Baseline characteristics of 
each cohort showed that patients who underwent BLT 
were younger but had significantly worse pre-transplant 
pulmonary function (mean FEV1 23.68 in BLT patients 
versus 44.11 in SLT, P<0.001). Similar to the findings 
demonstrated by Mason and colleagues, FEV1 and FVC 
peaked at 1-year post-transplantation for all transplant 
recipients. The BLT group had proportionally higher 
1-year post-transplantation FEV1 values. The authors 
hypothesized that worse spirometry results among SLT 
patients could be attributed to hyperinflation or progression 
of the underlying disease in the native lung. However, the 
extremely small sample size of each cohort should be noted. 
Pochettino observed improved pulmonary function 
and exercise tolerance in COPD recipients of bilateral 
transplantation (25). Similar to previous studies, they 
performed a single center retrospective study of 130 patients 
with emphysema from 1991–1999. Eighty-four patients 
underwent SLT and 46 patients underwent BLT. In addition 
to survival, the authors measured secondary outcomes of 
spirometry and 6-minute walk distances pre-operatively 
and at 3- to 6-month intervals post-operatively. While 
the authors prefer BLT (especially in younger patients) 
given their own institutional experience, they had utilized 
SLT on a more frequent basis due to scarcity of available 
donors. BLT was rarely utilized for recipients >60 years of 
age. Baseline FEV1, FVC, and 6-minute walk scores were 
similar between cohorts. At all post-transplantation time 
points during a 4-year observation period, BLT recipients 
exhibited higher FEV1 and FVC values compared to 
SLT, despite having similar baseline pulmonary function. 
Additionally, BLT patients had a higher mean 6-minute 
walk distance at all follow-up time points compared to 
SLT patients, with the difference ranging from 100 to 
400 feet. It should be noted that the comparisons of 
spirometry values and exercise tolerance in this study were 
not adjusted for confounding characteristics. For example, 
with the authors favoring the use of SLT in older recipients, 
the BLT recipients were measurably younger (51.1 versus 
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56.2 years, P<0.0001). In this sense, the SLT cohort was 
preferentially burdened by a group of patients with more 
advanced age, and presumably more comorbidities and 
frailty. Further assessment of comorbidity or pre-transplant 
disease severity was not performed. The authors concluded 
with their preference for BLT in younger recipients due 
to the superior functional results and quality-of-life payoff 
the bilateral approach affords. The degree to which their a 
priori programmatic adoption of a BLT strategy for younger 
recipients created this appearance of improved function is 
impossible to measure.
Gerbase performed a combined prospective analysis 
of post-transplantation functional status and QOL (26). 
Focusing on spirometry and 6-minute walk distance, 
they prospectively enrolled 44 patients prior to lung 
transplantation. Fourteen (32%) eventually received 
SLT, while the remainder received BLT. Spirometry 
measurements and exercise assessment were performed 
before the transplant, as well as 6 and 12 months post-
transplantation. Patients included in the report were 
followed for at least 2 years post-transplantation, raising 
some concerns about “survivor bias” and challenging the 
degree to which the result apply to patients on the waiting 
list. Although transplantation provided higher FEV1% 
predicted compared to baseline in all patients, this effect 
was dramatically lower among SLT recipients. At each time 
point over four years post-transplantation, SLT patients 
consistently had spirometry values at least 20% lower than 
spirometry scores of BLT recipients. 6MWT distances were 
not significantly different between cohorts, however. 
Instead of spirometry, Genao utilized a comprehensive 
performance score (Karnofsky performance score, 
KPS) to gauge functional status in older lung transplant 
recipients (27). Genao wanted to characterize the long-
term (1–5 years post-transplantation) trajectory of physical 
function, and subsequently analyze trends in older 
(>65 years) recipients of single and bilateral lung 
transplants. The authors performed a retrospective review 
of 4,805 patients listed in the UNOS registry between 
2005 and 2009. Of these, 774 patients were at least 65 years 
of age, and 63% of this older subset received SLT. They 
began their analysis at 11 months post-transplantation 
based on the assumption that all patients would naturally 
undergo a postoperative period of disability and functional 
recovery within the first year after transplantation. KPS 
were assessed for all patients. The KPS was initially 
developed in the 1940s, and was a clinician-rated measure 
that estimated the patient’s ability to conduct his or her 
daily activities/self-care with none, some, or complete 
assistance. The score ranges from 0 to 100, and a score of 
60 or less was traditionally associated with a higher risk 
for hospitalizations, the need for clinic visits, a serious 
functional decline, or mortality (28). The authors found 
that mean KPS scores at 1-year post-transplantation were 
higher than seen prior to transplantation for all recipients. 
One-year post-transplantation KPS was, on average, 2.6 
points higher (on the scale of 100) for BLT than SLT 
recipients (P<0.0001). In subsequent years, there was an 
average 3.2 points decline for all patients, regardless of 
transplantation type. While BLT was associated with higher 
KPS post-transplantation, the authors noted that it was very 
rare for patients of either group to reach a level of disability 
predictive of poor outcomes (KPS ≤60) within the 5-year 
follow-up period. Thus, Genao and colleagues were unable 
to support the use of BLT in older recipients based on 
predicted KPS scores. There were important limitations to 
this study. The authors cautioned that conclusions regarding 
use of BLT vs. SLT based on their findings should be 
tempered, as they were unable to control for comorbidities 
or provider preference. Additionally, the study took into 
account the immediate perioperative functional decline 
associated with the recovery period of transplantation 
and included only patients were alive and had KPS scores 
after 11 months post-procedure. However, they did not 
discuss how they handled longitudinal measurement of 
KPS scores in patients who died after the 11-month cutoff. 
If QOL measurements were only taken from those who 
survived, there could be a survivor bias associated with the 
results. Additionally, the authors mention that the KPS is 
a clinician-based assessment, and is not a patient reported 
outcome instrument. Clinician assessment of a patient’s 
QOL can vary from the individual patient’s experience and 
the clinician might be biased when assigning such scores. 
Post-transplantation QOL outcomes
For most patients with end-stage lung disease, lung 
transplantation cannot only provide a survival advantage, 
but can also influence dramatic changes in health-related 
QOL (HRQL). The most significant gains in HRQL are 
expected to be seen in physical health and functioning, 
and the greatest improvements are expected to occur early 
(within the first 6 months) after transplant (26). After 
1 year, the risk of onset of BOS and the effect of other 
patient comorbidities can blunt the effect of transplantation 
on HRQL (29). Research into patient-centered outcomes 
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in the field of lung transplantation has received growing 
attention over recent years. However, the available 
literature on this topic is relatively lacking, and there are 
even fewer studies that attempt to examine the influence of 
transplantation type on QOL. 
Certain cross-sectional studies have asserted a positive 
effect of BLT on HRQL measures. Anyanwu performed 
a European multicenter cross-sectional study of 255 lung 
transplant recipients (30). They administered the EuroQOL 
5D (EQ5D) and visual analog scale (VAS) health-utility 
instruments to patients who received bilateral (n=79), single 
(n=106) and heart-lung (n=70) transplants. The EQ5D 
defines health quality in five dimensions: mobility, self-
care, usual activities, pain and discomfort, and anxiety or 
depression (30,31). Survey takers can assign one of three 
labels to each dimension: no problem, moderate problem, 
or severe problem. Utility scores can then be assigned 
to each of these health states using regression analysis. 
The VAS allows participants to subjectively assess their 
own health on a scale of 0 to 100 (worst possible health 
to best possible health). In addition to stratifying results 
by transplant type, the authors repeated surveys at four 
different post-transplant time periods: 0–6, 7–18, 19–36, 
and >36 months. Problems in all five EQ5D domains in all 
time periods were more common among SLT patients than 
BLT patients. Those who received bilateral or combined 
heart-lung transplants had significantly higher EQ5D 
and VAS scores than their SLT counterparts in all time 
groups after 6 months (P=0.001). However, this study was 
limited by the lack of controlling for age and pre-transplant 
diagnosis. 
The positive impact of BLT on HRQL was not 
demonstrated by all studies. Gerbase administered the 
St. George’s Respiratory Questionnaire (SGRQ) and the 
VAS to 34 patients who had undergone SLT (n=14) or 
BLT (n=30) (26). The SGRQ primarily addresses three 
areas: respiratory symptoms, accomplishment of routine 
activities and disease impact on daily life (32). These 
patients were followed for at least 2 years (when the authors 
believed average onset of BOS occurs) and all data were 
collected prospectively. The authors noted that SGRQ and 
VAS scores were significantly improved after transplant 
compared to pre-transplant in both SLT and BLT groups. 
However, post-transplant, there was no significant 
differences in QOL scores between SLT and BLT groups. 
Scores were also independent of the underlying disease 
that led to transplantation. As described in the previous 
section, the authors also collected spirometric and 6MWT 
data and found that the post-transplantation improvement 
in FEV1% predicted scores were significantly less in SLT 
versus BLT recipients. 6MWTs were comparable between 
cohorts. The authors suggested that pulmonary function 
had limited influence on objective and subjective parameters 
of patient health-related QOL. 
Copeland prospectively studied QOL measures in 
patients who were 1-year post-transplantation (33). They 
utilized a pre-existing study cohort of 131 lung transplant 
patients who were already prospectively enrolled in a 
cytomegalovirus (CMV) prevention trial. To obtain data on 
physical and mental health QOL measures, they surveyed 
these patients immediately pre-transplant, as well as 3, 6, 9, 
and 12 months after transplant using the Medical Outcomes 
Study 36-Item Short-Form Health Survey (SF-36). 
As a part of the SF-36, scores are assigned to develop the 
Physical Component Survey and Mental Component 
Survey (34). These scores were followed longitudinally 
over the first post-transplant year. The authors used linear 
mixed modeling for repeated measures of QOL scores, 
which relied on any data collected at any time point to 
longitudinally estimate scores. This approach was used 
because the authors anticipated missing data from loss 
to follow-up or death. Over this time period, Physical 
Component Survey scores rose by an average of 10.9 
points from baseline (P<0.0001), reaching a level close 
to the average US population score. Mental Component 
Survey scores did not exhibit a significantly dramatic rise. 
When stratified by transplant type, bilateral operations 
did not confer a significant advantage in gains in physical 
component scores over single lung transplant. Given that 
the functional outcome benefit conferred by bilateral 
procedures has been shown to be greater in the long term 
(>1 year), it would be interesting to see if there would be a 
clinically important difference in QOL scores if they were 
longitudinally followed over a longer period of time.
Associations between procedure type and 
chronic rejection
BOS syndrome after lung transplantation represents 
chronic allograft rejection and dysfunction (35). BOS 
syndrome is defined as a progressive airflow obstruction 
with deterioration of graft function, and affects up to 60% 
of lung transplant recipients who survive 5 years post-
transplantation (36). The mean time between transplant 
and diagnosis is approximately 16–20 months (35). It 
has been characterized by a continuous deterioration in 
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FEV1% predicted, and can be pathologically confirmed by 
the presence of intraluminal fibromyxoid granulation tissue 
and extensive eosinophilic infiltrates on transbronchial 
biopsy (37). 
BOS has been linked to many poor outcomes in transplant 
recipients, with increased mortality risk and an association 
with decreased functional and HRQL outcomes (35). 
While the exact physiologic mechanism behind the 
development of BOS is unknown, multiple studies 
have reported SLT as a risk factor for development of 
BOS (26,38,39). Neurohr and colleagues performed an 
institutional review of their lung transplant database and 
compared 46 SLT and 30 BLT recipients with a diagnosis of 
IPF (38). SLT was found to be a predictor for occurrence of 
BOS ≥ stage 1. Another small institutional study performed 
by Gerbase, who noted that risk of BOS development at 
24 months post-transplant was more than two times higher 
in SLT recipients (RR 2.86; 95% CI, 1.22–6.67) (26). 
Hadjiliadis found SLT to be independently associated with 
BOS occurrence after transplantation (39). In their single 
center retrospective study of 225 transplant recipients, they 
found an overall incidence of BOS to be 41.3% at a median 
time of 4.2 years since transplant. After controlling for other 
patient comorbidities and characteristics, SLT was found to 
be significantly associated with BOS onset in multivariable 
regression analysis. Other variables including transplant 
center, recipient age, and end-stage lung disease diagnosis 
were not associated with risk of BOS development. As 
diagnosis of BOS depends on the decline in FEV1%, it 
makes sense that SLT patients are at increased risk of BOS 
development. Unlike BLT patients, SLT patients still have 
a diseased native lung, and its deterioration over time 
contributes to their overall FEV1%. Thus, in a hypothetical 
situation where the recipient risk factors and donor lungs 
are equal, an SLT patient may have a higher baseline risk 
for meeting the threshold of a BOS diagnosis compared to a 
BLT patient simply due to native lung dysfunction. 
Transplant center, recipient age, re-sapient diagnosis, 
gender, acute rejection score and number of bronchoscopies 
in the first 6 months had no effect on the risk of BOS 
development. 
Not all studies have demonstrated the same association 
between transplantation type and onset of BOS. In a much 
larger UNOS database analysis of 2,260 lung transplant 
recipients with primary diagnosis of COPD, Meyer and 
colleagues did not observe a difference in BOS incidence 
between SLT and BLT cohorts over the three-year follow-
up period (4). Given the enormous morbidity and mortality 
burden that BOS imposes on lung transplant recipients, 
further research is warranted to investigate the physiologic 
mechanism of BOS and any possible link there may be to 
transplantation type. 
Ethical considerations
Much of the debate surrounding use of BLT or SLT stems 
from the ethical challenge of how best to make use of 
a limited resource: donor lungs. The persistent ethical 
dilemma surrounding lung transplantation is whether the 
possible broader societal benefits of splitting a pair of donor 
lungs and thus reducing wait list time and wait list mortality 
outweighs the cost to the individual recipient to forego 
BLT. Several institutions, including our own, routinely use 
BLT for most lung transplant recipients (10). This brings 
to head the ethical dilemma posed by BLT, and challenges 
the reader to decide whether increased individual benefit is 
worth the societal cost of fewer patients transplanted. 
Several groups have found innovative methods to 
determine the opportunity cost of providing bilateral 
operations. Anyanwu examined lung donors reported to the 
United Kingdom Cardiothoracic Transplant Audit between 
1995 and 1998 for whom both lungs were utilized (40). 
They examined survival, rejection, and infection of donor 
recipients of these lungs to make comparisons between 
single lung and bilateral lung recipients. One-year graft 
survival for single lung and bilateral lung blocks were 
similar (65% vs. 71%). Of donor blocks that went to SLT 
recipients, both grafts were functioning in 44% of donor 
blocks, both grafts failed in 14% of donor blocks, and one 
of the two lungs failed in 42% of donor blocks. The authors 
estimated that splitting a lung block for SLT produced 1.8 
survivors per donor block at 1-year post-transplant. One of 
the weaknesses in their study is that they did not stratify by 
clinical diagnosis, and they even included a large number of 
patients with CF and those undergoing re-transplantation 
in their analysis. In another study, Anyanwu and colleagues 
examined cost-effectiveness of transplantation versus 
medical therapy, and included additional comparisons of 
SLT and BLT (41). They determined that over a theoretical 
15-year period, transplantation (compared to remaining 
on the waitlist with medical therapy) provided 2.1 and 
3.3 quality-adjusted life-years (QALY) for SLT and BLT, 
respectively. The average cost of medical therapy for those 
not receiving a transplant during this period of time was 
$73,564. The costs of SLT and BLT were $176,640 and 
$180,528, respectively. Costs per each QALY gained were 
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$48,241 for SLT and $32,803 for BLT. Based on the cost 
per QALY gained, the authors concluded that SLT was the 
least cost-effective form of therapy for patients with end 
stage lung disease. However, they noted that they were 
unable to quantify the additional societal gain that would 
come from the SLT’s ability to treat more patients. Also, 
it may be possible that the cost to society would be more 
accurately measured in total cost and not cost per QALY. A 
plan of more single lung transplant operations will lead to 
more operations in general and more patients on the very 
expensive post-transplant medications. The broad use of 
single rather than bilateral operations could greatly increase 
the total cost of lung transplantation programs to a society 
or a payer.
Wang took into account not only the ethical challenges 
in offering one versus two lungs, but the effect of remaining 
on the transplant waiting list longer with the hopes to 
undergo bilateral transplantation (42). Utilizing data 
obtained from national UK transplant database, they 
performed a sequentially stratified proportional hazards 
model on 1,211 adult lung transplant patients to address 
the following question: “should I accept SLT if offered 
or should I remain on the waiting list in the hope that 
I will be offered BLT in the future.” They found that 
in patients with pulmonary fibrosis, SLT was associated 
with a significant reduction in mortality hazard relative to 
waiting for BLT (HR 0.81, 95% CI, 0.68–0.97, P=0.021). 
They concluded that for pulmonary fibrosis patients, 
accepting SLT outweighed remaining on the transplant 
list for a BLT by minimizing the high pre-transplant risk 
of death. There was no such benefit demonstrated in 
accepting SLT for patients with COPD, however. Munson 
and colleagues reached a different conclusion (43). They 
created a simulation of a lung transplant waitlist using 
actual post LAS implementation UNOS registry data to 
define waitlist size, donor frequency, waitlist mortality risk, 
and disease- and procedure-specific post-transplantation 
survival. They aimed to determine post-transplant survival 
associated with BLT versus SLT in the COPD population. 
They determined that SLT always increased the number 
of patients transplanted, without significant reductions 
in total post-transplant survival. A theoretical policy of 
uniform use of SLT in their model resulted in an absolute 
reduction in the risk of waitlist mortality of 4.2% among 
all listed patients. However, they noted that this pattern 
may not be reproducible once geographic donor variations 
are accounted for and could not be compared to other 
transplant disease indications. 
While the common ethical argument suggests that 
SLT may provide greater societal benefit by maximizing 
utilization of the existing donor pool, this may not be an 
accurate depiction. One study used the UNOS registry to 
study lung block utilization in all SLTs performed between 
1987 and 2011. There were 7,232 unique SLT donors 
identified. Of these donors, only 3,129 (43%) had both 
lungs used for SLT. The authors reported that more than 
200 potential donor lungs went unused annually since 
2005. Donor factors associated with the harvest and use 
of only one lung included type B/AB blood group, lower 
BSA, lower pO2, pulmonary infection, extended criteria 
donor status, and traumatic brain injury or anoxia as cause 
of death. This study challenged one of the long-standing 
utilitarian arguments in favor of SLT (44).
At our own institution, there is a greater preference to 
perform BLT in part due to the prevailing notion that two 
lungs provide patients with greater physiologic reserve (10). 
Given this assumption, we often use what might be 
considered “marginal” donor lungs for BLT for patients—
donor organs that would otherwise might be wasted if 
considered individually in single lung blocks and thus 
declined. Similarly, in geographic situations in which donor 
lungs are not considered by a large number of programs, the 
ability to use two lungs might allow a physically small donor 
to provide lung transplantation for a much larger recipient. 
Therefore, it is possible that there is an occasional situation 
in which the use of donor lungs is “both or none”. In this 
sense, BLT may expand donor lung utilization. Further 
research into the use of marginal donors/extended donor 
criteria and subsequent impact on lung resource allocation 
will be necessary to clarify the nuances in the BLT vs. SLT. 
The ethical considerations of BLT vs. SLT encourage 
surgeons and institutions to determine priorities: optimizing 
total number of potential recipients who get transplanted or 
enhancing post-transplant survival. It is likely that these two 
goals might be at odds with each other. While adopting SLT 
will definitely increase the number transplanted, this may 
come at the expense of post-transplant long-term survival. 
Implementation of the LAS on transplant lung allocation 
practices aims to reduce transplant waitlist mortality. 
However, much of the ethics surrounding the debate will be 
expressed by institutional preference and practice. 
The native lung: potential complications and 
risk of cancer
One special consideration for the use of SLT is the risk 
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of potential complications in the native lung. Native 
lungs already have diminished lung function secondary 
to underlying disease process, and the use of SLT can 
potentially impose the additional complications. Venuta 
and colleagues described their experience in native lung 
complications in an institutional review (45). From 
1991–1997, they reviewed 35 patients who received SLT, 
of which 11 patients experienced an early (<6 weeks) 
native lung complication. These complications included 
overinflation, pneumothorax, hemothorax, pneumonia, 
invasive aspergillosis, and active tuberculosis (which 
was present at time of initial transplant). These patients 
underwent a mix of medical and surgical therapy, with 
3 patients receiving an operation. Mortality was still high, 
with 6 of these patients dying within 6 months. King and 
colleagues also described their institutional experience 
with SLT, and also studied outcomes of pneumonectomy 
for native lungs that experienced complications (46). In 
180 single lung transplants performed from 1998–2008, 
25 patients (14%) experienced significant native lung 
complications. Of these, 11 patients went on to receive 
a pneumonectomy for non-small  cell  lung cancer 
(NSCLC), aspergilloma, bronchopleural fistula, and 
recurrent infection. Complication rates after receiving 
pneumonectomy were high (36.4%), but there was no in-
hospital mortality. Additionally, when comparing patients 
who received a pneumonectomy for a complication to 
those who did not experience a complication, there was 
no statistically significant difference in median survival 
(4.3 vs. 5.1 years). Thus, King concluded that while native 
lung complications impose serious morbidity and mortality, 
pneumonectomy could provide an acceptable solution. 
While these studies highlight the potentially serious 
morbidity and mortality of native lung complications, 
certain points should be noted. First, the data presented in 
these studies are of limited sample size and are relatively 
outdated. The perioperative management of transplant 
patients has undergone substantial improvement over the 
years, calling into question whether high volume SLT 
centers today would experience the high rate of native lung 
complications. While early recognition and management 
of native lung complications is important, the possibility of 
developing a native lung complication does not necessarily 
preclude the use of SLT.
One additional concern regarding SLT is the risk of 
cancer development in the native lung. Citing increased risk 
associated with long-term chronic lung disease, possible 
recipient smoking history, increased age, and potential 
adverse effects of immunotherapy, one review documented 
a 9% prevalence of primary lung cancer found in native 
lungs after SLT (47). Olland and colleagues acknowledged 
that surgical resection for early stage NSCLC of the native 
lung should be pursued when possible, but the effects of 
chronic lung disease and immunosuppression may make 
surgery more challenging than when compared to a non-
transplanted patient (47). Nevertheless, the benefits of 
a SLT may still outweigh the risks of a BLT in a patient 
with high LAS. Appropriate resource utilization should be 
geared towards thorough and aggressive surveillance for 
malignancy in high-risk SLT patients.
Future directions: SBLT? 
As a possible compromise between SLT and BLT, Hartwig 
and colleagues have proposed SBLT for high-risk patients 
with ILD (48). To mitigate perioperative morbidity 
and mortality risk and to preserve the observed long-
term benefit of BLT, these authors proposed utilization 
of SLT in some recipients and then relisting them for a 
subsequent contralateral SLT at a future date. Typically, an 
institution using this strategy will list individuals deemed 
to have higher perioperative risk (by age or comorbidity) 
to undergo SLT. After transplantation, these patients are 
reviewed for re-listing and all individuals who were noted 
to have acceptably low perioperative complications and 
reasonable functional status were considered. Re-listing 
for contralateral transplant was performed as soon as was 
clinically appropriate (as determined by adequate functional 
recovery and no presence of infection or rejection). The 
authors performed a matched cohort analysis with a primary 
outcome of survival. Twelve patients underwent SBLT, 
and matches were selected in a 1:2:2 ratio from SLT and 
BLT recipients with ILD and similar LAS score. When 
comparing characteristics between the first and second 
stages of the SBLT procedure, there were no significant 
differences between donor characteristics. LASs were 
significantly higher in the first stage compared to the 
second stage (48.6 vs. 24.5, P<0.01). When comparing 
between matched cases, the authors found no significant 
differences in survival. The authors thus proposed SBLT 
as an alternative to SLT and BLT. The concept of SBLT is 
intriguing, but the strategy itself is fraught with potential 
complications and ethical challenges. The authors noted 
that the staged bilateral option exposes patients to two 
operations, and there may be a pool of individuals who 
sustain the risks of a second procedure when they could 
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have done reasonably well with just the initial single lung 
transplant. Additionally, the existing knowledge on the 
immunologic consequences of receiving a second lung 
from a separate donor is relatively limited. It is unclear 
whether these patients will be at greater or reduced risk for 
developing lung allograft dysfunction long-term. From an 
ethical perspective, it is unclear whether SBLT truly results 
in a better redistribution of a limited resource. While 
more lungs would be available for use if individuals 
underwent a unilateral first stage operation instead of a 
BLT, many would ultimately reappear on the waitlist. It 
is unclear whether the second donor lung would achieve 
more benefit as a second implant for a staged procedure 
recipient or being utilized for a new patient who has 
never undergone transplantation. Although several 
important questions regarding use of SBLT exist, it still 
remains a controversial option and further investigation 
into the subject may be warranted.
Conclusions
BLT has grown in utilization among transplant centers 
nationally, and presents a useful option for patients with a 
variety of end-stage lung disease diagnoses. The increased 
adoption of BLT is likely reflective of increased comfort 
in practice among transplant surgeons and recognition of 
benefits measured by long-term survival and improvements 
in functional and QOL outcomes. However, much of 
the literature that examines the use of BLT versus SLT 
is conflicting, and the clinical picture is further nuanced 
by disease indication, age of recipient, donor lung quality 
and patient disease severity. Although it is our institutional 
preference to utilize BLT in our patient population when 
possible, we cannot recommend one procedure type 
over another given the lack of high quality evidence. 
Transplantation type will continue to be determined 
on an individual basis. The current clinical picture of 
transplantation in the post-LAS era is certainly different 
than before, but much of the existing data available is not 
yet reflective of this change. There will likely never be 
a randomized trial to clarify the respective roles of BLT 
and SLT. However, further large database analyses and 
prospective observational studies will be instrumental to 
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